KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 20925 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Impact of RoSCo-based preoperative risk stratification on early mobilization and short-term outcomes following robot-assisted laparoscopic partial nephrectomy for renal cell carcinoma: a single-center prospective study. PMID 40619492 · J Robot Surg · 2025-Jul-06 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Oral health literacy: effectiveness of a homegrown intervention among community-dwelling older Nigerians. PMID 40618144 · BMC Oral Health · 2025-Jul-05 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Mitapivat in adults with non-transfusion-dependent α-thalassaemia or β-thalassaemia (ENERGIZE): a phase 3, international, randomised, double-blind, placebo-controlled trial. PMID 40544857 · Lancet · 2025-Jul-05 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Thyroidectomy with or without postoperative radioiodine for patients with low-risk differentiated thyroid cancer in the UK (IoN): a randomised, multicentre, non-inferiority trial. PMID 40543520 · Lancet · 2025-Jul-05 The study is an oncology Phase 3 randomized trial with a primary time-to-event endpoint (recurrence-free survival) and reports original results. However, the intervention is radioiodine ablation, which is a radiopharmaceutical/localized therapy, not a systemic drug intervention as typically required for the oncology drug-trial cohort. Therefore, it does not meet the drug-intervention criterion.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Immune-mediated adverse events in the randomized phase 3 TOPAZ-1 study of durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. PMID 40622010 · Oncologist · 2025-Jul-04 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type no_km 0 Figure · 0 Panel · risk not_applicable
Effect of astaxanthin supplementation on cycling performance, muscle damage biomarkers and oxidative stress in young adults: a randomized controlled trial. PMID 40615903 · BMC Sports Sci Med Rehabil · 2025-Jul-04 This is a randomized controlled trial in healthy young adults evaluating astaxanthin supplementation for exercise performance and muscle damage. It is not an oncology study, does not involve human malignant neoplasms, does not report a time-to-event cancer efficacy endpoint (OS, PFS, DFS, etc.), and the intervention is a dietary supplement, not a drug.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Long-term efficacy and safety of pexidartinib in patients with tenosynovial giant cell tumor: final results of the ENLIVEN study. PMID 40613752 · Oncologist · 2025-Jul-04 The study is a Phase III, randomized, drug-intervention trial in human oncology with original final results, but the reported efficacy endpoints (ORR, DOR, PROs) are not time-to-event endpoints. No Kaplan-Meier curves, hazard ratios, or survival/time-to-event data are explicitly reported in the abstract.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
An example of drug repurposing: ebastine in combination with docetaxel as a treatment for metastatic castration-resistant prostate cancer-the EXUROC prostate study, a clinical trial protocol. PMID 40611014 · BMC Urol · 2025-Jul-04 方案论文未报告临床试验结果。
S B
严格 v3 独有 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Efficacy and safety of anamorelin in patients with metastatic urothelial carcinoma receiving systemic chemotherapy: a randomized controlled study. PMID 40592718 · Oncologist · 2025-Jul-04 Metadata confirms oncology, human, randomized, drug intervention, time-to-event endpoint, and original result. However, the required 'Phase III/IIIb or Phase II/III' evidence is not explicitly established in the title, abstract, or metadata, leaving 'phase3_or_definitive' as null. Without explicit confirmation of the definitive phase, eligibility cannot be set to true.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Trastuzumab plus lapatinib or chemotherapy in patients with HER2-overexpressed advanced breast cancer: a randomized, phase II trial (GIM12-TYPHER). PMID 40591514 · Oncologist · 2025-Jul-04 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Long-term safety analysis of pooled data for tislelizumab as monotherapy or in combination with chemotherapy in patients with advanced cancers. PMID 40578840 · Oncologist · 2025-Jul-04 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。
H S B
严格 v3 独有 excludedsafety_or_economic_primary_endpoint pending 0 Figure · 0 Panel · risk -
Multi-center phase II study of nab-paclitaxel plus camrelizumab versus nab-paclitaxel alone as second-line treatment for advanced gastric cancer. PMID 40554667 · Oncologist · 2025-Jul-04 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
The lifecycle and evolution of new regimens on the National Comprehensive Cancer Network Guidelines for newly diagnosed multiple myeloma. PMID 39719103 · Oncologist · 2025-Jul-04 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized no_km 0 Figure · 0 Panel · risk not_applicable
Supporting patients with advanced cancer and their spouses in parenting minor children: results of a randomized controlled trial. PMID 39703166 · Oncologist · 2025-Jul-04 The study is an oncology randomized controlled trial, but it is a psychosocial intervention trial without a drug intervention and does not report a time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Safety and quality of life with maintenance olaparib plus bevacizumab in older patients with ovarian cancer: subgroup analysis of PAOLA‑1/ENGOT-ov25. PMID 39673779 · Oncologist · 2025-Jul-04 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Induction chemotherapy plus chemoradiotherapy in esophageal cancer: long-term results and exploratory analyses of a randomized controlled trial. PMID 39584557 · Oncologist · 2025-Jul-04 The report is an oncology, human, randomized trial with a drug intervention and primary time-to-event efficacy endpoints (OS, PFS) presented as long-term final results. However, the trial phase is not explicitly stated as Phase III/IIIb or Phase II/III in the provided metadata or abstract, so eligibility cannot be definitively established.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Real-world effectiveness of palbociclib plus endocrine therapy in HR+/HER2- advanced breast cancer: final results from the POLARIS trial. PMID 39475418 · Oncologist · 2025-Jul-04 The study is excluded because it is not a randomized controlled trial. It is an observational, real-world cohort study, which does not meet the requirement for a randomized Phase III/IIIb or Phase II/III trial. While it is an oncology study with a drug intervention and reports time-to-event efficacy results, the lack of randomization and interventional trial phase makes it ineligible.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Somatostatin analogue continuation upon progression in patients with gastroenteropancreatic neuroendocrine tumour (SAUNA trial): a randomised controlled trial protocol. PMID 40615151 · BMJ Open · 2025-Jul-03 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Efficacy and safety of Tafolecimab in Chinese patients with type 2 diabetes and hypercholesterolemia: a post-hoc analysis of pooled data from three phase 3 trials. PMID 40611077 · Cardiovasc Diabetol · 2025-Jul-03 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Immune correlates analysis of mRNA-1345 RSV vaccine efficacy clinical trial. PMID 40610413 · Nat Commun · 2025-Jul-03 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer. PMID 40532178 · N Engl J Med · 2025-Jul-03 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Impact of mirikizumab treatment on fatigue in patients with moderately to severely active Crohn's disease: results from the phase 3 VIVID-1 study. PMID 40491246 · J Crohns Colitis · 2025-Jul-03 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Achievement of long-term treatment goals in upadacitinib-treated patients with moderately to severely active ulcerative colitis: a post hoc analysis of phase 3 trial data. PMID 40488552 · J Crohns Colitis · 2025-Jul-03 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Structured Exercise after Adjuvant Chemotherapy for Colon Cancer. PMID 40450658 · N Engl J Med · 2025-Jul-03 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. PMID 40353578 · N Engl J Med · 2025-Jul-03 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk. PMID 40337982 · N Engl J Med · 2025-Jul-03 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Isatuximab, carfilzomib, lenalidomide, and dexamethasone induction in newly diagnosed myeloma: analysis of the MIDAS trial. PMID 39841461 · Blood · 2025-Jul-03 The abstract reports on an induction phase analysis of a Phase III trial with a drug-containing regimen, but it does not report a primary or key secondary time-to-event efficacy endpoint. It focuses on response rates, MRD negativity, safety, and stem cell collection. The study is ongoing with continued follow-up required. Therefore, it does not meet the core requirement for a time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Nivolumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Korean Patients with HER2-Negative, Untreated, Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer: Subgroup Analysis of a Randomized, Multicenter, Double-Blind Phase 3 Trial (ATTRACTION-4). PMID 40610007 · Cancer Res Treat · 2025-Jul-02 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Seltoplasmid promotes ulcer healing versus placebo for treating patients with chronic limb-threatening ischemia: HOPE CLTI-2 trial. PMID 40221835 · Mol Ther · 2025-Jul-02 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Phase-II randomized study of carboplatin plus capecitabine versus 3-weekly cisplatin in locally advanced head-and-neck cancer patients undergoing concurrent chemoradiation (CARCAP-HN). PMID 41004292 · J Cancer Res Ther · 2025-Jul-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Modified Target Delineation and Moderately Hypofractionated Radiotherapy for High-Grade Glioma: A Randomized Clinical Trial. PMID 40705330 · JAMA Netw Open · 2025-Jul-01 The record describes a randomized clinical trial with drug intervention (temozolomide) and time-to-event endpoints (PFS, OS) in oncology, but the trial phase is not explicitly established as Phase III/IIIb or Phase II/III. The 'deterministic_review' signals 'phase3_evidence_unclear', and no publication type or text explicitly confirms a definitive phase. Therefore, the criterion for phase is not met.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Homelessness, Patient Navigation, and Lung Cancer Screening in a Health Center Setting: A Subgroup Analysis of a Randomized Clinical Trial. PMID 40674053 · JAMA Netw Open · 2025-Jul-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Durvalumab Alone or Combined With Novel Agents for Unresectable Stage III Non-Small Cell Lung Cancer: Update From the COAST Randomized Clinical Trial. PMID 40663352 · JAMA Netw Open · 2025-Jul-01 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Effects of 12-Week Dietary Inflammatory Index-Based Dietary Education on Frailty Status in Frail Patients with Colorectal Cancer: A Randomized Controlled Trial. PMID 40647307 · Nutrients · 2025-Jul-01 The study is a randomized controlled trial in oncology (colorectal cancer) with a primary result, but it fails two key eligibility criteria: (1) the intervention is a non-drug dietary education program, not a drug-containing intervention; (2) the primary outcomes are frailty phenotype, inflammatory biomarkers, nutritional status, and quality of life, not a time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Treating Chronic Hand Eczema with Upadacitinib: Insights from Clinical Trials and Real-World Experience. PMID 40627583 · J Drugs Dermatol · 2025-Jul-01 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Long-term implant survival in delayed breast reconstruction. PMID 40613789 · BJS Open · 2025-Jul-01 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
The effect of qigong on frailty in older cancer survivors: a randomised controlled trial. PMID 40613666 · Age Ageing · 2025-Jul-01 The study is a randomized controlled trial in human cancer survivors, meeting oncology and randomization criteria. However, it is excluded because it does not involve a drug-containing intervention (qigong vs. light exercise) and does not use a time-to-event efficacy endpoint (primary outcome is frailty reversal, a categorical binary outcome).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Quality of life and patient reported outcomes in the UK Mammo-50 randomised trial of annual versus less frequent mammographic surveillance in people with breast cancer aged 50 years and over. PMID 40598487 · Health Qual Life Outcomes · 2025-Jul-01 The study is a Phase III randomized oncology trial with results, but it does not meet the core eligibility criteria because it does not involve a drug-containing intervention (it compares mammographic surveillance schedules) and its primary endpoint is quality of life, not a time-to-event efficacy outcome like OS, PFS, or DFS.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Comparison between mixed reality with artificial algorithms and ultrasound in localization of anterior thigh flap perforators: a prospective randomized controlled study. PMID 40598466 · BMC Med · 2025-Jul-01 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Electives in the medical curriculum as applicable to biochemistry: impacts and insights of medical students. PMID 40598157 · BMC Med Educ · 2025-Jul-01 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Impact of the 5A nursing model on immune balance and lymph node metastasis in primary liver cancer patients post-CyberKnife treatment. PMID 40597871 · BMC Cancer · 2025-Jul-01 Excluded because the intervention is non-drug (nursing model + radiotherapy) and the trial phase is not confirmed as definitive (Phase III/IIIb or II/III).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy of vaccination therapy in newly diagnosed and recurrent glioblastoma patients: a meta-analysis. PMID 40597861 · BMC Cancer · 2025-Jul-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Palliative radiotherapy in symptomatic pelvic soft tissue tumors (PallSoft)- protocol for a national, randomized, non-inferiority study. PMID 40597814 · BMC Cancer · 2025-Jul-01 方案论文未报告临床试验结果。
H S B
严格 v3 独有 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Neoadjuvant chemoradiotherapy with or without PD-1/PD-L1 inhibitors in locally advanced rectal cancer: a systematic review and meta-analysis. PMID 40597782 · BMC Cancer · 2025-Jul-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
A phase 1 safety and feasibility trial of a ketogenic diet plus standard of care for patients with recently diagnosed glioblastoma. PMID 40595067 · Sci Rep · 2025-Jul-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Anlotinib plus camrelizumab and chemotherapy as first-line treatment in patients with advanced esophageal squamous cell carcinoma. PMID 40595001 · Sci Rep · 2025-Jul-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Levosimendan for postoperative subclinical heart failure after noncardiac surgery: a randomized, double-blinded, phase III trial. PMID 40593481 · Nat Commun · 2025-Jul-01 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Sintilimab and anlotinib with gemcitabine plus cisplatin in advanced biliary tract cancer: SAGC a randomized phase 2 trial. PMID 40593475 · Nat Commun · 2025-Jul-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Osimertinib plus chemotherapy versus osimertinib for patients with advanced NSCLC with concomitant EGFR and TP53 mutations: a prospective cohort study. PMID 40593014 · Sci Rep · 2025-Jul-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Bowel urgency in ulcerative colitis: effect of baseline urgency and change in urgency in response to mirikizumab. PMID 40591171 · J Patient Rep Outcomes · 2025-Jul-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -